DOCSLIB.ORG

Drug Interactions and Lethal Drug Combinations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Interactions and Lethal Drug Combinations J Clin Pathol: first published as 10.1136/jcp.s3-9.1.94 on 1 January 1975. Downloaded from J. clin. Path., 28, Suppl. (Roy. Coll. Path.), 9, 94-98 The drug dilemma-benefits and hazards Drug interactions and lethal drug combinations ALAN RICHENS From the Department of Clinical Pharmacology, St Bartholomew's Hospital, London Although the development of drugs of greater example, aspirin can displace oral anticoagulants potency and efficacy confers on the physician from their plasma-protein-binding sites, and in- increasing power to treat serious diseases, it also directly acting sympathomimetics contained in cough increases the number and seriousness of potential mixtures can cause a hypertensive crisis in patients adverse effects and drug interactions which can on monoamine oxidase inhibitors. Self-medication is occur. Most hospital patients receive more than one common, and often involves drugs obtained on drug at a time, the average number often being prescription for a previous illness. greater than five (Smith, Seidl, and Cluff, 1966). The 4 When several clinics or doctors are involved in incidence of drug reactions rises with the number of the care of a patient, one doctor may not be aware of drugs prescribed simultaneously. In patients pre- what another has prescribed. scribed one to five drugs the incidence of reactions is 5 When preparations which contain more than 18-6%, while in patients prescribed six or more one ingredient are prescribed by their trade names. it rises to 814 % (Hurwitz and Wade, 1969). There are a number of ways in which drugs may The Boston Collaborative Drug Surveillance interact. These will be outlined and illustrated in the Program (1972) surveyed the incidence of drug remainder of this paper. reactions in 9900 patients admitted to nine acute disease hospitals and one chronic disease hospital. Interactions before Administration There were 83 200 drugs administered, and 3600 adverse reactions occurred of which 6-9 % were due Some drugs are chemically or physically incom- to drug interactions. The most serious interactions patible in the forms in which they are presented for included depression of the central nervous system, administration. For example, thiopentone sodium injection is strongly alkaline and will cause hydrolysis severe hypotension, gastrointestinal bleeding, psy- http://jcp.bmj.com/ chotic behaviour and superinfection. Although the of suxamethonium if both drugs are drawn up into clinical importance of drug interactions has been a syringe together for combined anaesthetic induc- exaggerated in some reports, the number which end tion and muscle relaxation. The excess of protamine in a fatal outcome is disproportionately high. In a zinc in protamine zinc insulin will combine with survey of 6199 medical inpatients in five general soluble insulin if the two preparations are mixed in hospitals and one chronic disease hospital, 744 the syringe before injection, resulting in a change in patients died in hospital, and of these deaths 27 were the rate of absorption of the latter preparation. As a considered to be due to drug treatment, of which nine general rule drug solutions should not be mixed, nor on October 1, 2021 by guest. Protected copyright. were caused by drug interactions (Shapiro, Slone, added to intravenous infusions, particularly whole Lewis, and Jick, 1971). blood, unless it is known that the components are The physician should be alert to the danger of chemically and physically compatible. drug interactions in a number of circumstances. Interactions in the Gut 1 When the pharmacological effect of a drug is harmful in excess and when the therapeutic ratio is Drugs are absorbed largely in the upper part of the low. Examples are hypoglycaemic drugs, anti- small intestine because of the enormous mucosal coagulants, digoxin, depressants of the central surface area and blood supply present there. Drugs nervous system, cytotoxic drugs. which alter the rate of gastric emptying can affect the 2 When a drug produces an altered state of delivery of the drug to this site and can thereby receptor sensitivity in the sympathetic nerve ter- influence either the rate or the extent of absorption. minals, eg, monoamine oxidase inhibitors (MA0Is), The anticholinergic properties of propantheline tricyclic antidepressants, hypotensive drugs. reduce the rate of gastric emptying and therefore 3 When interactions occur with medicines that slow down the absorption ofa drug such as paraceta- can be bought over the chemist's counter. For mol (Prescott, 1974). However, the extent of absorp- 94 J Clin Pathol: first published as 10.1136/jcp.s3-9.1.94 on 1 January 1975. Downloaded from Drug interactions and lethal drug combinations 95 tion, particularly of poorly soluble drugs like metabolism is substantially reduced by inhibition of digoxin, may be increased. As many drugs possess the metabolic enzyme. It is probable that this partly anticholinergic effects, eg, antihistamines, tricyclic accounts for the hypertensive crisis which can result antidepressants, phenothiazines and anti-Parkin- from the administration of directly acting sympa- sonian drugs, this type of interaction probably thomimetic amines, eg, tyramine, ephedrine, levo- occurs commonly. Metoclopramide increases the dopa, to patients on chronic MAOI therapy. An rate of gastric emptying, particularly in patients in interaction at the sympathetic nerve terminal is also whom it is delayed, and has been shown to shorten important in causing the crisis (see below). the time to peak plasma concentration of paraceta- The administration of dopa decarboxylase inhi- mol and aspirin (Prescott, 1974; Volans, 1974). bitors, eg, carbidopa in Sinemet, or benserazide in Some drugs may interact chemically in the gut, Madopar, probably increases the quantity of leading to impaired absorption of both drugs. levodopa which reaches the systemic circulation Calcium, magnesium and aluminium ions contained unmetabolized, as well as reducing its peripheral in antacid preparations cause the formation of a metabolism in tissues which contain the enzyme, metal-tetracycline chelate which is poorly absorbed such as sympathetic nerve terminals. In this case the (Kunin and Finland, 1961). Iron salts given simul- interaction is used to advantage because the amount taneously for anaemia will have a similar effect of levodopa which has to be administered daily to (Neuvonen and Turakka, 1974). These interactions the Parkinsonian patient can be reduced to between may result in an inadequate serum concentration of a quarter and a fifth by the addition of the enzyme the antibiotic being reached, with consequent inhibitor. failure of therapy. Chemical interaction in the gut It is likely that long-term therapy with liver- appears to account also for the failure of griseoful- enzyme-inducing drugs such as barbiturates can vin's antifungal action in patients receiving a reduce the quantity of other drugs reaching the barbiturate drug (Riegelman, Rowland, and Epstein, systemic circulation by increasing their first-pass 1970), and the reduction in plasma rifampicin metabolism, although it is not easy to distinguish concentrations by concurrent administration of this type of interaction from one involving a reduc- para-aminosalicylate (Boman, Hanngren, Malm- tion in absorption from the gut. borg, Borga, and Sjoqvist, 1971). Although barbi- turates are known to induce the hepatic metabolism Plasma-protein-binding Interactions of oral anticoagulants, it has been suggested that an interaction in the gut lumen might also contribute Many drugs are loosely bound to plasma proteins, to the lowering of the serum level of the anti- usually albumin. Only the unbound drug molecules coagulant (O'Reilly and Aggeler, 1969). are available for pharmacological action, although A deficiency of vitamin K in a patient treated with as they are removed from the circulation by distri- http://jcp.bmj.com/ oral anticoagulants will exaggerate the effect of bution or elimination they are replaced by other these latter compounds. Commensal organisms in molecules detaching themselves from protein- the gut produce vitamin K and therefore gut binding sites. A number of drugs are extensively sterilization with broad-spectrum antibiotics may bound to plasma proteins and therefore competition disturb anticoagulant control. Ingestion of liquid for binding sites can be a cause of drug interaction, paraffin may have the same effect because of the fat- although it is not easy to predict which drugs are soluble nature of the vitamin. likely to interact in this way because different types of on October 1, 2021 by guest. Protected copyright. binding sites may be used by different drugs. On the Interactions during Absorption whole, it is probable that competition for binding sites is not often a cause of a clinically important Drugs which are absorbed from the gut enter the interaction. portal venous system and are therefore exposed to Although displacement of a proportion of a drug drug-metabolizing enzymes in the hepatic cells bound to plasma proteins will increase the concen- before they enter the systemic circulation. This tration of free drug in the serum and therefore its results in a considerable loss of drugs that are pharmacological effect, the extent to which it is metabolized rapidly on first passage through the increased is dependent upon the drug's distribution liver-the so-called 'first pass effect'. Examples of volume. Centrally acting drugs, eg, phenytoin, are drugs for which this is important are isoprenaline, usually highly lipid soluble and have a large distri- ephedrine, levodopa, propranolol, aspirin and bution volume. A small quantity displaced from nortriptyline. Drug interactions may alter the extent binding sites will therefore rapidly redistribute to of first pass metabolism. This is likely to be most other tissues and will not cause an important important when a normally high rate of first pass increase in the effects of the drug. Warfarin, however, J Clin Pathol: first published as 10.1136/jcp.s3-9.1.94 on 1 January 1975. Downloaded from 96 Alan Richens is both highly bound to plasma proteins (98-99%) tion (by enzyme induction). This latter type of and has a relatively small distribution volume.
Load more

Recommended publications
  • Definition of Controlled Substance Schedules
    UPDATED MARCH 2018 DEFINITION OF CONTROLLED SUBSTANCE SCHEDULES Drugs and other substances that are considered controlled substances under the Controlled Substances Act (CSA) are divided into five schedules. An updated and complete list of the schedules is published annually in Title 21 Code of Federal Regulations (C.F.R.) §§ 1308.11 through 1308.15. Substances are placed in their respective schedules based on whether they have a currently accepted medical use in treatment in the U.S., their relative abuse potential, and likelihood of causing dependence when abused. Examples of the drugs in each schedule are listed below. Schedule I Controlled Substances Substances in this schedule have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse. Some examples of substances listed in Schedule I are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), peyote, methaqualone, and 3,4- methylenedioxymethamphetamine ("Ecstasy"). Schedule II/IIN Controlled Substances (2/2N) Substances in this schedule have a high potential for abuse which may lead to severe psychological or physical dependence. Examples of Schedule II narcotics include: hydromorphone (Dilaudid®), methadone (Dolophine®), meperidine (Demerol®), oxycodone (OxyContin®, Percocet®), and fentanyl (Sublimaze®, Duragesic®). Other Schedule II narcotics include: morphine, opium, codeine, and hydrocodone. Examples of Schedule IIN stimulants include: amphetamine (Dexedrine®, Adderall®), methamphetamine (Desoxyn®), and methylphenidate (Ritalin®). Other Schedule II substances include: amobarbital, glutethimide, and pentobarbital. 1 Schedule III/IIIN Controlled Substances (3/3N) Substances in this schedule have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence.
    [Show full text]
  • Comparison of Short-And Long-Acting Benzodiazepine-Receptor Agonists
    J Pharmacol Sci 107, 277 – 284 (2008)3 Journal of Pharmacological Sciences ©2008 The Japanese Pharmacological Society Full Paper Comparison of Short- and Long-Acting Benzodiazepine-Receptor Agonists With Different Receptor Selectivity on Motor Coordination and Muscle Relaxation Following Thiopental-Induced Anesthesia in Mice Mamoru Tanaka1, Katsuya Suemaru1,2,*, Shinichi Watanabe1, Ranji Cui2, Bingjin Li2, and Hiroaki Araki1,2 1Division of Pharmacy, Ehime University Hospital, Shitsukawa, Toon, Ehime 791-0295, Japan 2Department of Clinical Pharmacology and Pharmacy, Neuroscience, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 791-0295, Japan Received November 7, 2007; Accepted May 15, 2008 Abstract. In this study, we compared the effects of Type I benzodiazepine receptor–selective agonists (zolpidem, quazepam) and Type I/II non-selective agonists (zopiclone, triazolam, nitrazepam) with either an ultra-short action (zolpidem, zopiclone, triazolam) or long action (quazepam, nitrazepam) on motor coordination (rota-rod test) and muscle relaxation (traction test) following the recovery from thiopental-induced anesthesia (20 mg/kg) in ddY mice. Zolpidem (3 mg/kg), zopiclone (6 mg/kg), and triazolam (0.3 mg/kg) similarly caused an approximately 2-fold prolongation of the thiopental-induced anesthesia. Nitrazepam (1 mg/kg) and quazepam (3 mg/kg) showed a 6- or 10-fold prolongation of the anesthesia, respectively. Zolpidem and zopiclone had no effect on the rota-rod and traction test. Moreover, zolpidem did not affect motor coordination and caused no muscle relaxation following the recovery from the thiopental-induced anesthesia. However, zopiclone significantly impaired the motor coordination at the beginning of the recovery. Triazolam significantly impaired the motor coordination and muscle relaxant activity by itself, and these impairments were markedly exacerbated after the recovery from anesthesia.
    [Show full text]
  • Red with Nitrazepam and Placebo in Acute Emergency Driving Situations and in Monotonous Simulated Driving
    109 A 1986 The Carry-over Effects of Triazolam Compa- red with Nitrazepam and Placebo in Acute Emergency Driving Situations and in Mono- tonous Simulated Driving Hans Laurell and Jan Törnroos Reprint from Acta Pharmacologica et toxicologica 1986 v Väg06/7 Efi/( Statens väg- och trafikinstitut (VTI) * 581 01 Linköping [St]tlltet Swedish Road and Traffic Research Institute * S-581 01 Linköping Sweden Acta pharmacol. et toxicol. 1986, 58, 182186. From the National Swedish Road and Traffic Research Institute, (V.T.I.), S-58 101 Linköping, Sweden The Carry-over Effects of Triazolam Compared with Nitrazepam and Placebo in Acute Emergency Driving Situations and in Monotonous Simulated Driving Hans Laurell and Jan Törnros (Received October 9, 1985; Accepted January 9, 1986) Abstract: Eighteen healthy volunteers of both sexes, aged 2034, were tested in the morning while undertaking real car driving avoidance manoeuvres and during monotonous simulated driving after 1 and 3 nights of medication with triazolam 0.25 mg, nitrazepam 5 mg or placebo. The study was a double-blind, randomized, cross-over study, where a minimum of 7 days wash-out separated the 3 treatment periods. Nitrazepam was found to impair performance in the simulated task after 1 but not after 3 nights of medication. Performance in the triazolam condition was not signicantly different from the other conditions on this task on either day. However, after one night of medication triazolam tended to score worse than placebo but better than nitrazepam. In real car driving a tendency was noted for nitrazepam to score worst, whereas the difference between placebo and triazolam was hardly noticeable.
    [Show full text]
  • Calculating Equivalent Doses of Oral Benzodiazepines
    Calculating equivalent doses of oral benzodiazepines Background Benzodiazepines are the most commonly used anxiolytics and hypnotics (1). There are major differences in potency between different benzodiazepines and this difference in potency is important when switching from one benzodiazepine to another (2). Benzodiazepines also differ markedly in the speed in which they are metabolised and eliminated. With repeated daily dosing accumulation occurs and high concentrations can build up in the body (mainly in fatty tissues) (2). The degree of sedation that they induce also varies, making it difficult to determine exact equivalents (3). Answer Advice on benzodiazepine conversion NB: Before using Table 1, read the notes below and the Limitations statement at the end of this document. Switching benzodiazepines may be advantageous for a variety of reasons, e.g. to a drug with a different half-life pre-discontinuation (4) or in the event of non-availability of a specific benzodiazepine. With relatively short-acting benzodiazepines such as alprazolam and lorazepam, it is not possible to achieve a smooth decline in blood and tissue concentrations during benzodiazepine withdrawal. These drugs are eliminated fairly rapidly with the result that concentrations fluctuate with peaks and troughs between each dose. It is necessary to take the tablets several times a day and many people experience a "mini-withdrawal", sometimes a craving, between each dose. For people withdrawing from these potent, short-acting drugs it has been advised that they switch to an equivalent dose of a benzodiazepine with a long half life such as diazepam (5). Diazepam is available as 2mg tablets which can be halved to give 1mg doses.
    [Show full text]
  • Drug-Facilitated Sexual Assault Panel, Blood
    DRUG-FACILITATED SEXUAL ASSAULT PANEL, BLOOD Blood Specimens (Order Code 70500) Alcohols Analgesics, cont. Anticonvulsants, cont. Antihistamines, cont. Ethanol Phenylbutazone Phenytoin Cyclizine Amphetamines Piroxicam Pregabalin Diphenhydramine Amphetamine Salicylic Acid* Primidone Doxylamine BDB Sulindac* Topiramate Fexofenadine Benzphetamine Tapentadol Zonisamide Guaifenesin Ephedrine Tizanidine Antidepressants Hydroxyzine MDA Tolmetin Amitriptyline Loratadine MDMA Tramadol Amoxapine Oxymetazoline* Mescaline* Anesthetics Bupropion Pyrilamine Methcathinone Benzocaine Citalopram Tetrahydrozoline Methamphetamine Bupivacaine Clomipramine Triprolidine Phentermine Etomidate Desipramine Antipsychotics PMA Ketamine Desmethylclomipramine 9-hydroxyrisperidone Phenylpropanolamine Lidocaine Dosulepin Aripiprazole Pseudoephedrine Mepivacaine Doxepin Buspirone Analgesics Methoxetamine Duloxetine Chlorpromazine Acetaminophen Midazolam Fluoxetine Clozapine Baclofen Norketamine Fluvoxamine Fluphenazine Buprenorphine Pramoxine* Imipramine Haloperidol Carisoprodol Procaine 1,3-chlorophenylpiperazine (mCPP) Mesoridazine Cyclobenzaprine Rocuronium Mianserin* Norclozapine Diclofenac Ropivacaine Mirtazapine Olanzapine Etodolac Antibiotics Nefazodone Perphenazine Fenoprofen Azithromycin* Nordoxepin Pimozide Hydroxychloroquine Chloramphenicol* Norfluoxetine Prochlorperazine Ibuprofen Ciprofloxacin* Norsertraline Quetiapine Ketoprofen Clindamycin* Nortriptyline Risperidone Ketorolac Erythromycin* Norvenlafaxine Thioridazine Meclofenamic Acid* Levofloxacin* Paroxetine
    [Show full text]
  • Treatment of Myoclonus with Pheneturide
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.41.7.598 on 1 July 1978. Downloaded from Journal ofNeurology, Neurosurgery, andPsychiatry, 1978, 41, 598-602 Treatment of myoclonus with pheneturide C. D. WARD From the Royal Hospital, Sheffield S U M M A R Y Twenty-one patients with various forms of myoclonus are presented. Phena- cemide was given to five patients with considerable benefit to three, but with serious toxic effects in two. Another acetylurea derivative, pheneturide, was given to 19 patients and was well tolerated. Myoclonus was completely or substantially controlled in 12 patients. The term "myoclonus" may be applied to very between 1965 and 1976. They had displayed myo- abrupt involuntary movements which are neur- clonic jerks and had been treated with phena- onally determined, asynergic, and arrhythmic. An cemide or pheneturide. Of these patients, 16 were assortment of involuntary movements share these seen personally for review and three responded to characteristics but differ in their relationship to a questionnaire. Records of outpatient follow-up movement, relaxation, posture, or sensory stimuli, were available for one patient who had died and Protected by copyright. and in their anatomical disposition (Gasaut, 1968); for one who could not be traced. All had given a they may involve parts of muscles, whole muscles, history of repeated, instantaneous involuntary or, more usually, muscle groups. Such movements, movements and had reported at least one of the collectively termed myoclonus, are seen in a wide following: sudden jerks of the arms causing ob- variety of pathological conditions (Halliday, 1967) jects to fly out of the hands; sudden interruption and may often be associated with epilepsy.
    [Show full text]
  • Intermittent Treatment of Febrile Convulsions with Nitrazepam Michel Vanasse, Pierre Masson, Guy Geoffroy, Albert Larbrisseau and Pierre C
    LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES Intermittent Treatment of Febrile Convulsions with Nitrazepam Michel Vanasse, Pierre Masson, Guy Geoffroy, Albert Larbrisseau and Pierre C. David ABSTRACT: Intermittent oral or rectal administration of diazepam for the prophylactic treatment of febriie convulsions has given results comparable to the continuous use of phenobarbital while limiting side effects and risks of toxicity. Since we believe that nitrazepam is a better anticonvulsant than diazepam, we performed a study to evaluate the effectiveness of this medication in the prophylactic treatment of febrile convulsions. Nitrazepam was given only when the children had fever and almost exclusively in children with a high risk of recurrence (less than 12 months of age at first convulsion; atypical convulsion; one or several previous convulsions). Thirty one children with a high risk of recurrence received nitrazepam. The rate of recurrence in this group was 19.3% after a follow-up of 16 months, compared to 45.8% in 24 children who also had a high risk of recurrence but in whom the parents refused the medication or gave it inadequately (p<0.05). Fifty one children with a low risk of recurrence also were evaluated and followed for at least 12 months (mean 15.4 months). Six were treated with nitrazepam, mostly because of parental anxiety, and none had a recurrence; of the 45 untreated children in this group, 6 (13.6%) had another convulsion. These results show the efficiency of nitrazepam in the prophylactic treatment of febrile convulsions. RESUME: L'utilisation intermittente du diazepam par voie orale ou rectale pour le traitement prophylactique des convulsions febriles a donne d'aussi bons resultats que l'utilisation continue du phenobarbital.
    [Show full text]
  • FINAL STUDY PROTOCOL Utilisation of Antiepileptic Medicines in Girls
    FINAL STUDY PROTOCOL Utilisation of antiepileptic medicines in girls and women of childbearing potential - a study in three European countries Prepared for the European Medicines Agency May 2017 Version 2.0 Approved 15th May 2017 EUROmediSAFE Consortium 1 TABLE OF CONTENTS Page 1. Background 3 2. Aims 4 3. Data sources 5 4. Methods 6 5. Statistical analyses 12 6. Sample size 15 7. Strengths and limitations 15 8. Study report and manuscript 17 9. Communication of study results 17 10. Ethical and data access approvals 17 11. Milestones 18 12. Quality control 18 13. Data access, storage and sharing 18 14. Protocol authors 20 15. Amendments and deviations from the protocol 20 Appendix I 21 2 1. BACKGROUND In October 2013, the Medicines and Healthcare Regulatory Authority issued a referral into the use of sodium valproate in girls and women of childbearing potential, following new evidence in the literature relating to an increased risk of neurodevelopmental disorders in children exposed to sodium valproate in-utero. The review was carried out by the Pharmacovigilance Risk Assessment Committee (PRAC) and in October 2014 the PRAC adopted its recommendation. Following completion of the review, a letter was sent to healthcare professionals in January 2015 informing them of the changes in the recommendations for valproate prescribing. The recommendations resulting from the review included that Valproate and related substances should not be used in female children, women of childbearing potential and pregnant women unless alternative treatments are ineffective or not tolerated. Valproate and related substances should be contraindicated in prophylaxis of migraine attacks in pregnancy and women of childbearing potential who are not using effective methods of contraception during treatment with valproate.
    [Show full text]
  • Commonly Abused Prescription and Otc Medications
    C OMMONLY A BUSED P RESCRIPTION AND OTC MEDIcaTIONS Substance Examples of Commercial and Street Names DEPRESSANTS barbiturates Amytal, Nembutal, Seconal, Phenobarbital; barbs, reds, red birds, phennies, tooies, yellows, yellow jackets Benzodiazepines Ativan, Halcion, Librium, Valium, Xanax; candy, downers, sleeping (other than flunitrazepam) pills, tranks Flunitrazepam Rohypnol; forget-me pill, Mexican Valium, R2, Roche, roofies, (associated with sexual assaults; roofinol, rope, rophies not sold in US, but may be brought in) OPIOIDS AND MORPHINE DERIVATIVES codeine Empirin with Codeine, Fiorinal with Codeine, Robitussin A-C, Tylenol with Codeine; Captain Cody, Cody, schoolboy; (with glutethimide) doors & fours, loads, pancakes and syrup fentanyl and fentanyl analogs Actiq (oral), Duragesic (patch), Sublimaze; Apache, China girl, China white, dance fever, goodfella, jackpot, murder 8, TNT, Tango & Cash morphine Roxanol, Duramorph; M, Miss Emma, monkey, white stuff oxycodone HCL Oxycontin; Oxy, O.C., killer hydrocodone bitartrate, acetaminophen Vicodin; vike, Watson-387 STIMULANTS amphetamine Biphetamine, Dexedrine, Adderall; bennies, black beauties, crosses, hearts, LA turnaround, speed, truck drivers, uppers methylphenidate Ritalin; JIF, MPH, R-ball, Skippy, the smart drug, vitamin R (safe & effective for treatment of ADHD) OVER-THE-COUNTER (OTC) MEDICATION Dextromethorphan (DXM) Found in any cold medicine with “DM” or “Tuss” in the title or name; Orange Crush, Triple C’s, C-C-C, Red Devils, Skittles, Dex, Vitamin D, Robo, Robo-trippin’,
    [Show full text]
  • Chloral Hydrate: Summary Report
    Chloral Hydrate: Summary Report Item Type Report Authors Yuen, Melissa V.; Gianturco, Stephanie L.; Pavlech, Laura L.; Storm, Kathena D.; Yoon, SeJeong; Mattingly, Ashlee N. Publication Date 2020-02 Keywords Compounding; Food, Drug, and Cosmetic Act, Section 503B; Food and Drug Administration; Outsourcing facility; Drug compounding; Legislation, Drug; United States Food and Drug Administration; Chloral Hydrate Rights Attribution-NoDerivatives 4.0 International Download date 26/09/2021 09:06:16 Item License http://creativecommons.org/licenses/by-nd/4.0/ Link to Item http://hdl.handle.net/10713/12087 Summary Report Chloral Hydrate Prepared for: Food and Drug Administration Clinical use of bulk drug substances nominated for inclusion on the 503B Bulks List Grant number: 2U01FD005946 Prepared by: University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) University of Maryland School of Pharmacy February 2020 This report was supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award (U01FD005946) totaling $2,342,364, with 100 percent funded by the FDA/HHS. The contents are those of the authors and do not necessarily represent the official views of, nor an endorsement by, the FDA/HHS or the U.S. Government. 1 Table of Contents REVIEW OF NOMINATION ..................................................................................................... 4 METHODOLOGY ...................................................................................................................
    [Show full text]
  • The Risk of Specific Congenital Anomalies in Relation to Newer Antiepileptic Drugs
    Drugs - Real World Outcomes (2016) 3:131–143 DOI 10.1007/s40801-016-0078-1 REVIEW ARTICLE The Risk of Specific Congenital Anomalies in Relation to Newer Antiepileptic Drugs: A Literature Review 1 2 1 Josta de Jong • Ester Garne • Lolkje T. W. de Jong-van den Berg • Hao Wang1 Published online: 24 May 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com Abstract found. The signals for associations between topiramate and Background More information is needed about possible cleft lip with/without cleft palate and hypospadias were associations between the newer anti-epileptic drugs considered strong. Associations between lamotrigine and (AEDs) in the first trimester of pregnancy and specific anencephaly and transposition of great vessels were found congenital anomalies of the fetus. within one study and were not supported by other studies. Objectives We performed a literature review to find sig- No signals were found for the other newer AEDs, or the nals for potential associations between newer AEDs information was too limited to provide such a signal. (lamotrigine, topiramate, levetiracetam, gabapentin, Conclusion In terms of associations between monotherapy oxcarbazepine, eslicarbazepine, felbamate, lacosamide, with a newer AED in the first trimester of pregnancy and a pregabalin, retigabine, rufinamide, stiripentol, tiagabine, specific congenital anomaly, the signals for topiramate and vigabatrin, and zonisamide) and specific congenital cleft lip with/without cleft palate and hypospadias should anomalies. be investigated further. Methods We searched PubMed and EMBASE to find observational studies with pregnancies exposed to newer AEDs and detailed information on congenital anomalies. Key Points The congenital anomalies in the studies were classified according to the congenital anomaly subgroups of Euro- Information was found on specific congenital pean Surveillance of Congenital Anomalies (EUROCAT).
    [Show full text]
  • Antiepileptic Drugs: Evolution of Our Knowledge and Changes in Drug Trials
    ILAE 110th anniversary review paper* Epileptic Disord 2019; 21 (4): 319-29 Antiepileptic drugs: evolution of our knowledge and changes in drug trials Emilio Perucca Past President of the International League Against Epilepsy Division of Clinical and Experimental Pharmacology, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia and IRCCS Mondino Foundation, Pavia, Italy Received April 30, 2019; Accepted June 01, 2019 ABSTRACT – Clinical trials provide the evidence needed for rational use of medicines. The evolution of drug trials follows largely the evolution of regulatory requirements. This article summarizes methodological changes in antiepileptic drug trials and associated advances in knowledge starting from 1938, the year phenytoin was introduced and also the year when evi- dence of safety was made a requirement for the marketing of medicines in the United States. The first period (1938-1969) saw the introduction of over 20 new drugs for epilepsy, many of which did not withstand the test of time. Only few well controlled trials were completed in that period and trial designs were generally suboptimal due to methodological constraints. The intermediate period (1970-1988) did not see the introduction of any major new medication, but important therapeutic advances took place due to improved understanding of the properties of available drugs. The value of therapeutic drug monitoring and monotherapy were recognized dur- ing the intermediate period, which also saw major improvements in trial methodology. The last period (1989-2019) was dominated by the introduc- tion of second-generation drugs, and further evolution in the design of monotherapy and adjunctive-therapy trials. The expansion of the pharma- cological armamentarium has improved opportunities for tailoring drug treatment to the characteristics of the individual.
    [Show full text]